Insider Buying: Enovis (NYSE:ENOV) Insider Acquires $100,024.40 in Stock

Key Points

• Enovis insider Oliver Engert purchased 5,140 shares at an average price of $19.46, investing $100,024.40 and increasing his ownership by 9.16% to 61,238 shares.
• Enovis shares fell 4.2% to $18.58, near the company’s 12-month low of $18.52. The stock trades well below its 50-day and 200-day moving averages.
• The company exceeded quarterly earnings and revenue expectations, while analysts maintain a consensus “Moderate Buy” rating with an average price target of $40.38; institutional investors own 98.45% of the stock.

Enovis Corporation (NYSE:ENOV - Get Free Report) insider Oliver Engert purchased 5,140 shares of the business's stock in a transaction dated Thursday, September 3rd. The shares were purchased at an average price of $19.46 per share, for a total transaction of $100,024.40. Following the acquisition, the insider owned 61,238 shares of the company's stock, valued at approximately $1,191,691.48. The trade was a 9.16% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Oliver Engert also recently made the following trade(s):

• On Monday, June 15th, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were purchased at an average cost of $20.92 per share, with a total value of $20,920.00.
• On Thursday, June 11th, Oliver Engert acquired 1,200 shares of Enovis stock. The stock was purchased at an average price of $21.62 per share, with a total value of $25,944.00.
• On Wednesday, June 10th, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was acquired at an average cost of $23.00 per share, for a total transaction of $23,000.00.

Enovis Stock Down 4.2%

ENOV traded down $0.82 during trading on Friday, hitting $18.58. 1,886,327 shares of the company's stock traded hands, compared to its average volume of 1,200,013. The company's 50 day simple moving average is $25.50 and its two-hundred day simple moving average is $24.20. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. Enovis Corporation has a 12-month low of $18.52 and a 12-month high of $34.28. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -0.96 and a beta of 1.31.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The firm had revenue of $582.78 million during the quarter, compared to analysts' expectations of $581.84 million. During the same quarter in the previous year, the business earned $0.79 earnings per share. The company's revenue was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts predict that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enovis

Several institutional investors have recently made changes to their positions in the business. Rubric Capital Management LP purchased a new position in shares of Enovis in the third quarter worth approximately $83,435,000. Paradigm Capital Management Inc. NY bought a new position in Enovis in the second quarter worth approximately $28,533,000. California State Teachers Retirement System boosted its stake in shares of Enovis by 1,635.6% during the 2nd quarter. California State Teachers Retirement System now owns 1,335,833 shares of the company's stock worth $27,652,000 after acquiring an additional 1,258,867 shares during the last quarter. Bank of America Corp DE purchased a new position in shares of Enovis during the 2nd quarter worth $11,502,000. Finally, AQR Capital Management LLC grew its position in shares of Enovis by 682.6% during the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company's stock valued at $15,627,000 after acquiring an additional 434,646 shares during the period. Institutional investors own 98.45% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. UBS Group reaffirmed a "buy" rating and set a $51.00 price target (up from $50.00) on shares of Enovis in a report on Tuesday, July 28th. BTIG Research decreased their price objective on shares of Enovis from $40.00 to $36.00 and set a "buy" rating for the company in a report on Tuesday. Citigroup reissued a "market outperform" rating on shares of Enovis in a report on Wednesday. Evercore set a $32.00 target price on shares of Enovis in a research note on Monday, July 6th. Finally, Zacks Research raised Enovis from a "strong sell" rating to a "hold" rating in a report on Wednesday, July 29th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Enovis has a consensus rating of "Moderate Buy" and an average target price of $40.38.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source